Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

In this episode, Urology Times® Assistant Editor Janelle Hart spoke with Amy D. Dobberfuhl, MD, MS, about the presentation, “Feasibility and efficacy of transvaginal onabotulinumtoxinA chemodenervation of the trigone for the third line treatment of refractory overactive bladder,” which was given at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction Winter Meeting. Dobberfuhl is a urologist at Stanford Hospitals and Clinics and an assistant professor of urology at the Stanford University School of Medicine in California.